PDF(Pubmed)
Abstract：
UNASSIGNED: Currently, there is a lack of well-established markers to predict the efficacy of chemoimmunotherapy in small-cell lung cancer (SCLC). Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), advanced lung cancer inflammation index (ALI) and prognostic nutritional index (PNI) are associated with prognosis in several tumors, whereas their predictive role in SCLC remains unclear.
UNASSIGNED: A retrospective study was conducted at Sun Yat-sen University Cancer Center, involving extensive-stage SCLC (ES-SCLC) patients who received first-line chemoimmunotherapy between January 2020 and December 2021. Peripheral blood biomarkers were extracted from medical records and their correlation with prognosis and immune-related adverse events (IRAEs) was analyzed.
UNASSIGNED: A total of 114 patients were included. Patients with a low PLR, high ALI and high PNI had prolonged progression-free survival (PFS) compared to those with a high PLR, low ALI and low PNI. Patients with a low NLR, low PLR, high ALI and high PNI had prolonged overall survival (OS) compared to those with a high NLR, high PLR, low ALI and low PNI. Cox regression model showed that PNI was an independent risk factor for both PFS and OS. ROC curve showed that PNI outperforms NLR, PLR and ALI in predicting both PFS and OS. The PNI-based nomogram demonstrated strong predictive capability for both PFS and OS. In addition, there was a significant correlation between PNI and IRAEs.
UNASSIGNED: A high baseline PNI might be associated with improved prognosis and the occurrence of IRAEs in ES-SCLC patients treated with first-line chemoimmunotherapy.
UNASSIGNED: A retrospective study was conducted at Sun Yat-sen University Cancer Center, involving extensive-stage SCLC (ES-SCLC) patients who received first-line chemoimmunotherapy between January 2020 and December 2021. Peripheral blood biomarkers were extracted from medical records and their correlation with prognosis and immune-related adverse events (IRAEs) was analyzed.
UNASSIGNED: A total of 114 patients were included. Patients with a low PLR, high ALI and high PNI had prolonged progression-free survival (PFS) compared to those with a high PLR, low ALI and low PNI. Patients with a low NLR, low PLR, high ALI and high PNI had prolonged overall survival (OS) compared to those with a high NLR, high PLR, low ALI and low PNI. Cox regression model showed that PNI was an independent risk factor for both PFS and OS. ROC curve showed that PNI outperforms NLR, PLR and ALI in predicting both PFS and OS. The PNI-based nomogram demonstrated strong predictive capability for both PFS and OS. In addition, there was a significant correlation between PNI and IRAEs.
UNASSIGNED: A high baseline PNI might be associated with improved prognosis and the occurrence of IRAEs in ES-SCLC patients treated with first-line chemoimmunotherapy.
摘要：
■目前，目前缺乏公认的标志物来预测小细胞肺癌(SCLC)化学免疫疗法的疗效.中性粒细胞与淋巴细胞比率（NLR），血小板与淋巴细胞比率（PLR），晚期肺癌炎症指数(ALI)和预后营养指数(PNI)与多种肿瘤的预后相关,而其在SCLC中的预测作用尚不清楚.
■在中山大学肿瘤防治中心进行了一项回顾性研究，涉及2020年1月至2021年12月期间接受一线化学免疫治疗的广泛阶段SCLC（ES-SCLC）患者。从病历中提取外周血生物标志物，分析其与预后和免疫相关不良事件（IRAE）的相关性。
■共纳入114例患者。PLR低的患者，与高PLR的患者相比，高ALI和高PNI的无进展生存期（PFS）延长，低ALI和低PNI。NLR低的患者，PLR低,与NLR高的患者相比，高ALI和高PNI的总生存期（OS）延长，PLR高,低ALI和低PNI。Cox回归模型显示，PNI是PFS和OS的独立危险因素。ROC曲线显示PNI优于NLR，PLR和ALI在预测PFS和OS中的应用。基于PNI的列线图显示了对PFS和OS的强大预测能力。此外,PNI和IRAEs之间存在显著相关性。
■在接受一线化学免疫疗法治疗的ES-SCLC患者中，高基线PNI可能与预后改善和IRAE的发生有关。
■在中山大学肿瘤防治中心进行了一项回顾性研究，涉及2020年1月至2021年12月期间接受一线化学免疫治疗的广泛阶段SCLC（ES-SCLC）患者。从病历中提取外周血生物标志物，分析其与预后和免疫相关不良事件（IRAE）的相关性。
■共纳入114例患者。PLR低的患者，与高PLR的患者相比，高ALI和高PNI的无进展生存期（PFS）延长，低ALI和低PNI。NLR低的患者，PLR低,与NLR高的患者相比，高ALI和高PNI的总生存期（OS）延长，PLR高,低ALI和低PNI。Cox回归模型显示，PNI是PFS和OS的独立危险因素。ROC曲线显示PNI优于NLR，PLR和ALI在预测PFS和OS中的应用。基于PNI的列线图显示了对PFS和OS的强大预测能力。此外,PNI和IRAEs之间存在显著相关性。
■在接受一线化学免疫疗法治疗的ES-SCLC患者中，高基线PNI可能与预后改善和IRAE的发生有关。
